Mycophenolate Mofetil Ameliorates Diabetic Nephropathy in dbdb Mice

Abstract EN

Chronic low-grade inflammation is an important factor in the pathogenesis of diabetic complication.

Mycophenolate mofetil (MMF) has an anti-inflammatory effect, inhibiting lymphocyte proliferation.

Previous studies showed attenuation of diabetic nephropathy with MMF, but the underlying mechanisms were unclear.

This study aimed to identify the effect of MMF on diabetic nephropathy and investigate its action mechanisms in type 2 diabetic mice model.

Eight-week-old db/db and control mice (db/m mice) received vehicle or MMF at a dose of 30 mg/kg/day for 12 weeks.

MMF-treated diabetic mice showed decreased albuminuria, attenuated mesangial expansion, and profibrotic mRNA expressions despite the high glucose level.

The number of infiltrated CD4+ and CD8+ T cells in the kidney was significantly decreased in MMF-treated db/db mice and it resulted in attenuating elevated intrarenal TNF-α and IL-17.

The renal chemokines expression and macrophages infiltration were also attenuated by MMF treatment.

The decreased expression of glomerular nephrin and WT1 was recovered with MMF treatment.

MMF prevented the progression of diabetic nephropathy in db/db mice independent of glycemic control.

These results suggest that the effects of MMF in diabetic nephropathy are mediated by CD4+ T cell regulation and related cytokines.